Replies to post #244643 on Biotech Values

[DewDiligence]

YMAB’s Omburtamab rejected by CHMP:

https://www.globenewswire.com/news-release/2022/12/16/2575746/0/en/The-CHMP-has-Adopted-a-Negative-Opinion-for-Omburtamab-for-the-Treatment-of-CNS-LM-Metastasis-from-Neuroblastoma-in-Europe.html

CHMP considered that it was not possible to conclude on the effectiveness of omburtamab as the main study did not have a randomized comparator.

An admonition for those who might think NWBO has an approvable dataset.

YMAB is down only 5% in AH trading; the CHMP’s rejection is hardly surprising given the FDA’s CRL two weeks ago for essentially the same reason (#msg-170587417).

[DewDiligence]

YMAB acquired at $8.60/sh cash—a 105% premium to yesterday’s closing price:

https://www.globenewswire.com/news-release/2025/08/05/3127378/0/en/SERB-Pharmaceuticals-Agrees-to-Acquire-Y-mAbs-Therapeutics.html

The buyer is SERB Pharma, a private company based in Pennsylvania that specializes in drugs for emergency care. The nominal deal value is $412M.